top of page
2189263545-huge_edited.jpg
HOME: Welcome
refinements-1_edited.png

Scientific innovation leading to the restoration, preservation, and improvement of patient vision

HOME: About

ABOUT AMBER

Amber Ophthalmics is a clinical stage biopharmaceutical company formed in 2020, focused on driving novel therapeutics for rare anterior segment ophthalmic diseases

Proven leadership team brings experience in multiple therapeutic areas and novel modalties, ensuring innovation translates to patient benefit

Driving lead clinical candidate, NEXAGON for the treatment of persistent corneal epithelial defects (PCED)

refinements-1_edited_edited.png
HOME: Services

CORNEAL SURFACE DISEASE

Corneal surface disease encompasses a wide variety of conditions affecting the ocular surface. These conditions include dry eye disease, blepharitis, meibomian gland dysfunction, immunologic disorders and persistent corneal epithelial defects. (1)

PERSISTENT CORNEAL EPITHELIAL DEFECT (PCED)

DEFINITION

PCED is a rare, progressive disease defined as prolonged loss of the corneal epithelium, caused by a variety of underlying etiologies. (2) 

EPIDEMIOLOGY

Over 100,000 patients in the United States are diagnosed annually, with as many as an estimated 50% progressing to corneal melt, the final stage before perforation, despite treatment. (3,4)

TREATMENT

Standard of care (SOC) can include lubrication and therapeutic contact lens, with refractory patients receiving autologous serum drops and ultimately, surgical intervention. There is no FDA approved treatment for PCED. (2)

refinements-1_edited_edited.png

NEXAGON (LUFEPIRSEN OPHTHALMIC GEL)

Unmet Medical Need

Despite standard of care, patients remain at risk for corneal transplant or vision loss 

Underserved >$1B market (3)

Novel Mechanism

Proprietary MOA that addresses the common underlying pathology of PCED

Differentiated Product Profile

NEXAGON recognized as a potential paradigm shift to current therapy

Clinical Evaluation

NEX-PED-005 Clinical Study: 

PCED secondary to chem./therm. injury

AMB-01-006 Clinical Study: 

PCED 

refinements-1_edited_edited.png

BUSINESS DEVELOPMENT

Amber Ophthalmics is positioned
for continued growth through
program acquisition, in-licensing
and partnering of
development stage assets.
Please contact us to find out more.

CONTACT

Amber Ophthalmics is located in sunny San Diego! Please contact us using the link below. We look forward to hearing from you.

REFERENCES

  1. Lim L, Lim EWL. Therapeutic Contact Lenses in the Treatment of Corneal and Ocular Surface Diseases-A Review. Asia Pac J Ophthalmol (Phila). 2020 Dec;9(6):524-532.

  2. Golhait P, Peseyie R. Persistent Epithelial Defect. In: StatPearls. StatPearls Publishing, Treasure Island (FL); 2021. PMID: 34424633

  3. DelveInsight, Persistent Epithelial Defects (PED) Market Insights, Epidemiology and Market Forecast - 2030; (2020)

  4. Guidehouse Independent US PED Epidemiology Refresh (2021)

bottom of page